Lepu Biotech (02157): CMG901 (AZD0901) clinical study results will be selected for LBA and a total of 4 clinical study results will be announced at the Chairman's seminar and selected for the 2026 ESMO Conference

Zhitongcaijing · 1d ago

Zhitong Finance App News, Lepu Biotech (02157) issued an announcement at the 2026 Annual Meeting of the European Society of Oncology Medicine (ESMO Conference 2026): (1) Positive positive CMG901 positive phase III clinical trial of second-line and backline (2L+) Claudin 18.2 positive advanced metastatic gastroesophageal cancer (GEC) will be selected for the Major Research Summary (LBA) and will present a selected paper report at the Chairman's seminar; (2) MRG007 (a potential similar type for treating colorectal cancer (CRC)) The positive results of the phase I clinical study of the best CDH17 targeted antibody drug conjugate (ADC) drug candidate) were selected for the LBA and will be quickly presented orally at the conference;

(3) The positive results of the European phase II study on MRG003 and HX008 combination therapy for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) were selected for a quick oral report; and (4) the positive results of the phase II study of MRG003 and HX008 combination therapy for treating epidermal growth factor receptor-positive (EGFR positive) unresectable transient/underdifferentiated thyroid cancer were selected for rapid oral report.

The 2026 ESMO Conference will be held in Madrid, Spain from October 23 to 27, 2026 (local time). As one of the world's largest, most academically advanced and authoritative oncology conferences, the ESMO conference brought together leading experts, clinicians and clinical researchers in the field of oncology from around the world to discuss advanced treatment concepts and cutting-edge clinical and translational research advances in global cancer diagnosis and treatment.

CMG901 (AZD0901) is an ADC targeting CLDN18.2 developed jointly by the company and Connoya Biomedical Technology Co., Ltd. (Connoya). In February 2023, global rights to research, develop, register, manufacture and commercialize CMG901 were granted to AstraZeneca (AstraZeneca), and the detailed results of its phase III clinical trial for the treatment of second-line and above advanced/metastatic Claudin 18.2 positive GEC will be disclosed for the first time as an LBA at the ESMO Conference Chairman's Seminar. Meanwhile, the results of the Phase I clinical study of MRG007 (a potentially best-in-class CDH17 ADC for treating gastrointestinal malignancies) will also be revealed for the first time in the form of a quick oral report from the LBA at the 2026 ESMO conference.